Collegium Pharmaceutical, Inc.

COLL

US19459J1043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 17/07/2024 am IST			5-day change	1st Jan Change
31.95 ^USD	+0.53%		+0.92%	+3.80%

01/07	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index	CI
01/07	Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index	CI

Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index

July 01, 2024

Latest news about Collegium Pharmaceutical, Inc.

Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Growth-Defensive Index	01/07	CI
Collegium Pharmaceutical, Inc.(NasdaqGS:COLL) added to Russell 2000 Defensive Index	01/07	CI
Collegium Pharmaceutical Says Nucynta Gets FDA Pediatric Exclusivity	13/06	MT
Collegium Pharmaceutical, Inc. Obtains Six Month Extension of U.S. Pediatric Exclusivity for Nucynta Franchise	13/06	CI
Jefferies Upgrades Collegium Pharmaceutical to Buy From Hold, Adjusts Price Target to $44 From $41	07/06	MT
Collegium Pharmaceutical Insider Sold Shares Worth $814,180, According to a Recent SEC Filing	06/06	MT
Collegium Pharmaceutical Launches $35 Million Accelerated Share Repurchase Program	13/05	MT
Needham Downgrades Collegium Pharmaceutical to Hold From Buy	10/05	MT
Piper Downgrades Collegium Pharmaceutical to Neutral From Overweight, Price Target at $39	10/05	MT
Collegium Pharmaceutical Q1 Adjusted Net Income, Revenue Rise; 2024 Outlook Reiterated	10/05	MT
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Posts Q1 EPS $1.45, vs. Street Est of $1.47	10/05	MT
Collegium Pharmaceutical, Inc. Reaffirms Earnings Guidance for the Full Year 2024	10/05	CI
Transcript : Collegium Pharmaceutical, Inc., Q1 2024 Earnings Call, May 09, 2024	10/05
Tranche Update on Collegium Pharmaceutical, Inc.'s Equity Buyback Plan announced on January 3, 2024.	10/05	CI
Collegium Announces CEO Transition	10/05	CI
Collegium Announces President and Board Changes	10/05	CI
Collegium Pharmaceutical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER	29/04	CI
Collegium Pharmaceutical to Redeem $26.35 Million of Senior Notes	11/04	MT
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics	03/04	CI
Piper Sandler Adjusts Price Target on Collegium Pharmaceutical to $39 From $37, Maintains Overweight Rating	26/02	MT
Truist Adjusts Price Target on Collegium Pharmaceutical to $40 From $37, Maintains Buy Rating	26/02	MT
Collegium Pharmaceutical's Q4 Adjusted Earnings, Revenue Increase	23/02	MT
Transcript : Collegium Pharmaceutical, Inc., Q4 2023 Earnings Call, Feb 22, 2024	23/02
Earnings Flash (COLL) COLLEGIUM PHARMACEUTICAL Reports Q4 EPS $1.58, vs. Street Est of $1.26	23/02	MT

Chart Collegium Pharmaceutical, Inc.

Duration

Period

More charts

Collegium Pharmaceutical, Inc. is a diversified specialty pharmaceutical company. The Company commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta ER and Nucynta immediate-release (IR), Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is a pain treatment option designed with abuse deterrent properties and uses a technology platform, DETERx. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic. Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Symproic is used for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Collegium Pharmaceutical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

31.78 USD

Average target price

41 USD

Spread / Average Target

+29.01%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
COLLEGIUM PHARMACEUTICAL, INC.	+3.80%	103.97Cr
ELI LILLY AND COMPANY	+61.53%	86TCr
NOVO NORDISK A/S	+38.95%	63TCr
JOHNSON & JOHNSON	-3.66%	36TCr
MERCK & CO., INC.	+15.06%	32TCr
ABBVIE INC.	+9.18%	30TCr
ROCHE HOLDING AG	+5.89%	23TCr
NOVARTIS AG	+16.53%	23TCr
AMGEN INC.	+15.67%	18TCr
PFIZER, INC.	+2.47%	16TCr

Other Pharmaceuticals